Recent Updates
Recently added Catalysts
FDMT Positive Sentiment

Uneek Mehra speaks on a licensing and deal-making panel at BIO 2024

Friday, June 21, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Uneek Mehra, CFO & CBO of FDMT, participated in a panel at BIO 2024 titled 'A Licensing Deal for All Seasons.' The discussion focused on the lifecycle of deals, motivations from both buyers and sellers, and the impact of the macro environment on partnerships in the biotech and pharmaceutical industries.
Price reaction · baseline $22.61 (2024-06-20 close) · hit pre-market · 2 other FDMT headline(s) in the window, move may be shared
day 0 close · peak
+1.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Uneek Mehra's participation highlights company leadership.
  • The panel discusses important aspects of deal-making.
  • Focus on partnerships in the biotech and pharma sectors.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+128%
120-day peak, hindsight
Typical move
11.2%
average across 9 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
4D-150 IVT
Phase 3 · Macular Neovascularization Secondary to Age-Related Macular Degeneration

Full Press Release Details

22,321 followers
• Report this post
Earlier this week, our CFO & CBO, Uneek Mehra , participated in a #BIO2024 panel titled, “A Licensing Deal for All Seasons.” Uneek and the other panelists discussed the lifecycle of a deal, motivations and incentives from the sell and buy side, and how the overall macro environment shapes #partnerships and deals in #biotech and #pharma .
• Copy
• LinkedIn
• Facebook
• X
To view or add a comment, sign in

Frequently Asked Questions

What was the topic of Uneek Mehra's panel at BIO 2024?

The panel discussed the lifecycle of licensing deals and motivations from both sides.

Who participated in the BIO 2024 panel?

Uneek Mehra, CFO & CBO of FDMT, was a participant in the panel.

What is the significance of the macro environment in deal-making?

The macro environment influences partnerships and deals in the biotech and pharma sectors.

ShareAdd on Google
Tags: FDMT Viatris Investor Conferences Healthcare BIO 2024 licensing biotech pharma
Last updated: Jun 21, 2024

Biotech snapshot

Cash runway
$431M liquidity · $23M/mo burn
~18 mo
Low dilution risk
Lead asset
4D-150 IVTPhase 3
Macular Neovascularization Secondary to Age-Related Macular Degeneration →

Catalyst track record

+128%
best trade around FDMT's most recent catalyst

Peak hindsight return over a 120-day window, across 9 tracked FDA/PDUFA catalysts for FDMT.

See every catalyst's timing & PoA →